Lyell Immunopharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Phone
650 695-0677
Fiscal Year End
1231
EIN
833006753
Financial Overview
FY2025
$490.86M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-3 Shelf registration for future offerings | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 3 Initial insider ownership report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Clinical-stage biotechnology company focused on developing innovative T-cell therapies for solid tumors.
- LYL-101, the lead patient-specific T-cell therapy, advanced through Phase 1 clinical trials with initial data expected mid-2026.
Insider Trading
BUY
6 insiders
11 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.